<DOC>
	<DOCNO>NCT01915303</DOCNO>
	<brief_summary>This study ass whether pasireotide alone combine cabergoline give relief patient recurrent , persistent newly diagnose Cushing 's disease . The study also assess study drug safety , change Quality Life clinical sign symptoms Cushing 's disease .</brief_summary>
	<brief_title>Study Efficacy Safety Pasireotide s.c. +/- Cabergoline Patients With Cushing 's Disease</brief_title>
	<detailed_description>This study ass whether pasireotide alone combine cabergoline give relief patient recurrent , persistent newly diagnose Cushing 's disease . The study also assess study drug safety , change Quality Life clinical sign symptoms Cushing 's disease . The study consist pasireotide-untreated patient screen patient currently treat maximal tolerate dos pasireotide . Core phase consist pasireotide-untreated patient screen - include patient never receive pasireotide patient receive pasireotide sometime past discontinue safety . These patient start pasireotide 0.6mg twice day 8 week . Should biochemical control achieve dose increased 0.9mg twice day . If biochemical control still achieve , cabergoline increase dose add . Patients currently treat maximal tolerate dos pasireotide monotherapy least 8 week 0.3mg twice day , 0.6mg twice day 0.9mg twice day , still achieve biochemical control add cabergoline increase dose . After 35 week treatment core phase , patient option continue study treatment extension phase pasireotide yet approve commercial use and/or reimburse - country reimbursement applicable .</detailed_description>
	<mesh_term>Pituitary ACTH Hypersecretion</mesh_term>
	<mesh_term>ACTH-Secreting Pituitary Adenoma</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<criteria>Inclusion criterion : 1 . Written inform consent obtaine prior screen procedure 2 . Adult patient confirm diagnosis ACTHdependent Cushing 's disease evidence follow : 1 . The mean three 24hour urine sample collect within 2 week &gt; 1xULN 2 3 sample &gt; ULN 2 . Morning plasma ACTH within normal normal range 3 . Either MRI confirmation pituitary adenoma &gt; 6 mm , inferior petrosal sinus gradient &gt; 3 CRH stimulation patient tumor less equal 6 mm* . For patient prior pituitary surgery , histopathology confirm ACTH stain adenoma *If IPSS previously perform without CRH ( e.g . DDAVP ) , central peripheral prestimulation gradient &gt; 2 require . If IPSS previously perform , IPSS CRH stimulation require . 3 . Patients de novo Cushing 's disease include consider candidate pituitary surgery ( e.g . poor surgical candidate , surgically unapproachable tumor , patient refuse surgical treatment ) 4 . Male female patient age 18 year great 5 . Karnofsky performance status ≥ 60 ( i.e . require occasional assistance , able care personal need ) 6 . Patients medical treatment Cushing 's disease follow washout period must complete screen assessment perform Inhibitors steroidogenesis ( ketoconazole , metyrapone ) : 1 week Pituitary direct agent : Dopamine agonist ( bromocriptine , cabergoline ) PPARγ agonist ( rosiglitazone pioglitazone ) : 4 week Octreotide LAR , Lanreotide SR Lanreotide autogel : 14 week Octreotide ( immediate release formulation ) : 1 week Progesterone receptor antagonist ( mifepristone ) : 4 week 7 . Patients consider enter trial meet one follow criterion : 1 ) They naive pasireotide 2 ) They receive pasireotide past discontinue lack efficacy ( 2 week washout prior screen patient treat pasireotide subcutaneously 12 week washout prior screen patient treat pasireotide LAR ) 3 ) Patients maximal tolerate dose achieved biochemical control 8 . Women childbearing potential , defined woman physiologically capable become pregnant , use highly effective method contraception dose 30 day stop study medication . 9 . Male participant trial must agree use condom intercourse , father child study period 30 day follow stop study treatment . Exclusion criterion : 1 . Patients compression optic chiasm cause visual field defect require surgical intervention 2 . Diabetic patient poor glycemic control evidence HbA1c &gt; 8 % 3 . Patients risk factor torsade de pointes , i.e . patient baseline QTcF &gt; 450 m male , &gt; 460 m female . hypokalemia , hypomagnesaemia , uncontrolled hypothyroidism , family history long QT syndrome , concomitant medication know prolong QT interval . 4 . Patients clinically significant valvular disease . 5 . Patients Cushing 's syndrome due ectopic ACTH secretion 6 . Patients hypercortisolism secondary adrenal tumor nodular ( primary ) bilateral adrenal hyperplasia 7 . Patients congestive heart failure ( NYHA Class III IV ) , unstable angina , sustain ventricular tachycardia , clinically significant bradycardia , advanced heart block , history acute MI le one year prior study entry clinically significant impairment cardiovascular function 8 . Patients liver disease cirrhosis , chronic active hepatitis , chronic persistent hepatitis , patient ALT/AST &gt; 2 X ULN , serum bilirubin &gt; 2.0 X ULN 9 . Patients serum creatinine &gt; 2.0 X ULN 10 . Patients WBC &lt; 3 X 10e9/L ; Hb 90 % &lt; LLN ; PLT &lt; 100 X 10e9/L 11 . Patients presence Hepatitis B surface antigen ( HbsAg ) 12 . Patients presence Hepatitis C antibody test ( antiHCV ) 13 . Patients severe hepatic impairment ( Child Pugh C ) hypersensitivity pasireotide cabergoline 14 . Patients lung , pericardial , retroperitoneal fibrosis ; gastroduodenal ulcer digestive haemorrhage , galactose intolerance , Parkinson 's disease , uncontrolled hypertension Raynauds syndrome . 15 . Pregnant nursing ( lactate ) woman pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; 5 mIU/ml ) 16 . Patients endstage renal failure and/or hemodialysis 17 . Patients presence active suspect acute chronic uncontrolled infection 18 . Patients history noncomplance medical regimen consider potentially unreliable whill unable complete entire study 19 . Patients presence Hepatitis B surface antigen ( HbsAg ) 20 . Patients presence Hepatitis C antibody test ( antiHCV ) 21 . Patients severe hepatic impairment ( Child Pugh C ) hpersensitivity pasireotide cabergoline 22 . Patients lung , pericardial , retroperitoneal fibrosis ; gastroduodenal ulcer digestive haemorrhage , galactose intolerance , Parkinson 's disease , uncontrolled hypertension Raynaud 's syndrome 23 . Pregnant nursing ( lactate ) woman pregnancy define state female conception terminiation gestation , confirm positive hCG laboratory test ( &gt; 5mIU/mL ) 24 . Patients endstage renal failure and/or hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cushing 's disease , pituitary tumor , pasireotide , cabergoline , combination treatment , UFC , hormone disorder , cortisol , adrenocorticotropic hormone</keyword>
</DOC>